The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer
- PMID: 24550720
- PMCID: PMC3923659
- DOI: 10.1371/journal.pcbi.1003470
The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer
Abstract
Interleukin-1 (IL-1) is a large cytokine family closely related to innate immunity and inflammation. IL-1 proteins are key players in signaling pathways such as apoptosis, TLR, MAPK, NLR and NF-κB. The IL-1 pathway is also associated with cancer, and chronic inflammation increases the risk of tumor development via oncogenic mutations. Here we illustrate that the structures of interfaces between proteins in this pathway bearing the mutations may reveal how. Proteins are frequently regulated via their interactions, which can turn them ON or OFF. We show that oncogenic mutations are significantly at or adjoining interface regions, and can abolish (or enhance) the protein-protein interaction, making the protein constitutively active (or inactive, if it is a repressor). We combine known structures of protein-protein complexes and those that we have predicted for the IL-1 pathway, and integrate them with literature information. In the reconstructed pathway there are 104 interactions between proteins whose three dimensional structures are experimentally identified; only 15 have experimentally-determined structures of the interacting complexes. By predicting the protein-protein complexes throughout the pathway via the PRISM algorithm, the structural coverage increases from 15% to 71%. In silico mutagenesis and comparison of the predicted binding energies reveal the mechanisms of how oncogenic and single nucleotide polymorphism (SNP) mutations can abrogate the interactions or increase the binding affinity of the mutant to the native partner. Computational mapping of mutations on the interface of the predicted complexes may constitute a powerful strategy to explain the mechanisms of activation/inhibition. It can also help explain how an oncogenic mutation or SNP works.
Conflict of interest statement
I have read the journal's policy and have the following conflicts: Our co-author Ruth Nussinov serves as the editor-in-chief for this journal. Additionally, our corresponding author Ozlem Keskin serves as a Guest Associate Editor for this journal. This does not alter our adherence to all the PLOS Comp Biol policies on sharing data and materials. All other authors have declared that no competing interests exist.
Figures







References
-
- Dunn E, Sims JE, Nicklin MJ, O'Neill LA (2001) Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol 22: 533–536. - PubMed
-
- Pizarro TT, Cominelli F (2007) Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol 178: 5411–5412. - PubMed
-
- Sims JE, Nicklin MJ, Bazan JF, Barton JL, Busfield SJ, et al. (2001) A new nomenclature for IL-1-family genes. Trends Immunol 22: 536–537. - PubMed
-
- Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27: 229–265. - PubMed
-
- Farasat S, Aksentijevich I, Toro JR (2008) Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 144: 392–402. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous